

STRICTLY PRIVATE & CONFIDENTIAL

July 29, 2024

DELIVERED BY EMAIL

Antibe Therapeutics Inc. – Process Letter Update

To Whom It May Concern,

On behalf of Antibe Therapeutics Inc. (“**Antibe**” or the “**Company**”), we would like to thank you for your interest to date in the Company.

We are issuing this letter to inform you of an extension to the timeline (the “**Extension**”) of the Court-approved sale process (the “**Sale Process**”) regarding the potential acquisition of Antibe’s present and future assets, undertakings and real and personal property (the “**Property**”) either en bloc or in parts (the “**Transaction**”). Pursuant to the Extension, all future Sale Process milestone dates are hereby extended by fourteen (14) days. For clarity, the Phase 1 Bid Deadline is the first milestone date for which the Extension is applicable. All other procedures and information related to the Sale Process, as outlined in the initial Process Letter, remain unchanged.

The following table sets out the updated key milestone dates under the Sale Process:

Milestone	Date(s)
Commencement of Sale Process	June 11, 2024
Phase 1 Diligence Period	June 11-August 13, 2024
Phase 1 Bid Deadline	August 14, 2024
Assessment of Phase 1 Bids	August 15-23, 2024
Phase 2 Diligence Period	August 24-September 16, 2024
Phase 2 Bid Deadline	September 17, 2024
Auction Date (if required)	September 25, 2024
Finalize Transaction Agreement	September 25, 2024
Court Hearing for Sale Approval Motion	As soon as reasonably practicable, or October 4, 2024
Closing of the Transaction	As soon as reasonably practicable, or October 11, 2024

NOTE: Pursuant to the Court-approved terms of the Sale Process, dates set out in the Sale Process may be extended by either: (i) further order of the Court; or, (ii) the Receiver.

As the Transaction is subject to the Sale Process with specified requirements, each non-binding letter of intent (“**LOI**”) submitted for the Phase 1 Bid Deadline must be submitted before the **Phase 1 Bid Deadline of 1:00 PM (EST) on August 14, 2024**, and address the requirements outlined in the initial Process Letter.

Please submit your LOI and any applicable supporting documentation to Bloom Burton with copy to the Receiver and its legal counsel:

Bloom Burton

Jolyon Burton
Head of Investment Banking
(647) 328-7134
jburton@bloomburton.com

Claudia Hui
Vice President
(416) 454-6688
chui@bloomburton.com

David Philpott
Analyst
(647) 501-7946
dphilpott@bloomburton.com

Receiver and its Legal Counsel

Jim Robinson
Senior Managing Director
FTI Consulting Canada Inc.
(416) 649-8070
jim.robinson@fticonsulting.com

Jonathan Joffe
Senior Director
FTI Consulting Canada Inc.
(416) 274-4526
jonathan.joffe@fticonsulting.com

Rebecca Kennedy
Partner
Thornton Grout Finnigan LLP
(416) 304-0603
rkennedy@tgf.ca

Following assessment of the LOIs, Bloom Burton and the Receiver will select one or more parties who submitted LOIs to enter into Phase 2 of the Sale Process to complete additional required diligence. The deadline to receive final binding offers by the **Phase 2 Bid Deadline is 1 P.M. EST on September 17, 2024**. The target closing date for the Transaction will be on or before October 11, 2024.

Bloom Burton and the Receiver are available to consult with interested parties prior to submission of LOIs to clarify information requirements and procedures, and to answer your questions.

Thank you for your interest in Antibe and the resources you have invested in this process up to this point. We look forward to working with you further on this opportunity.

Sincerely yours,

Bloom Burton and FTI Consulting Canada Inc.